As filed with the Securities and Exchange Commission on August 5, 2024
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
AXSOME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
45-4241907 |
(State or other jurisdiction |
|
(IRS Employer Identification No.) |
of incorporation or organization) |
|
|
One World Trade Center
22nd Floor
New York, New York 10007
(Address of principal executive offices) (Zip Code)
Axsome Therapeutics, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan
(Full title of the Plans)
Herriot Tabuteau, M.D.
President and Chief Executive Officer
Axsome Therapeutics, Inc.
One World Trade Center
22nd Floor
New York, New York 10007
(Name and address of agent for service)
(212) 332-3241
(Telephone number, including area code, of agent for service)
Copies to:
|
|
Emilio Ragosa DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, New Jersey 07078 Telephone: (973) 520-2550 |
Hunter Murdock General Counsel Axsome Therapeutics, Inc. One World Trade Center 22nd Floor New York, NY 10007 Telephone: (212) 332-3241 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
Large accelerated filer ☒ |
|
Accelerated filer ☐ |
Non-accelerated filer ☐ |
|
Smaller reporting company ☐ |
|
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART II
Information Required in the Registration Statement
This Registration Statement relates to the registration of an additional 1,894,054 shares (the “Shares”) of the common stock, par value $0.0001 per share, of Axsome Therapeutics, Inc. (the “Registrant”). The Shares are securities of the same class and relate to the same employee benefit plan, the 2015 Omnibus Incentive Compensation Plan, as those registered pursuant to the Registrant’s registration statements on Form S-8, previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 16, 2015, March 29, 2017, August 13, 2018, March 15, 2019, May 11, 2020, May 11, 2021, May 2, 2022, and May 9, 2023. In accordance with General Instruction E of Form S-8, the contents of the Registrant’s registration statements on Form S-8 (File Nos. 333-208579, 333-217002, 333-226824, 333-230296, 333-238174, 333-256019, 333-264621, and 333-271741) filed with the SEC on December 16, 2015, March 29, 2017, August 13, 2018, March 15, 2019, May 11, 2020, May 11, 2021, May 2, 2022, and May 9, 2023 are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.
Item 8. Exhibits
|
|
|
Exhibit Number |
|
Exhibit |
|
|
|
5.1* |
|
Opinion and Consent of DLA Piper LLP (US). |
|
|
|
23.1* |
|
Consent of DLA Piper LLP (US) is contained in Exhibit 5.1. |
|
|
|
23.2* |
|
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm. |
|
|
|
23.3* |
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. |
|
|
|
24.1* |
|
Power of Attorney. Reference is made to page 3 of this Registration Statement. |
|
|
|
99.1 |
|
Axsome Therapeutics, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 10.2 to Registrant’s Annual Report on Form 10-K, filed on February 23, 2024). |
|
|
|
99.2 |
|
Axsome Therapeutics, Inc. Form of Stock Option Agreement pursuant to the Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 99.2 to Registrant’s Registration Statement on Form S-8, File No. 333-208579, filed December 16, 2015). |
|
|
|
99.3 |
|
Axsome Therapeutics, Inc. Form of Restricted Stock Unit Agreement (Non-Executives) pursuant to the Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 99.3 to the Company’s Registration Statement on Form S-8 (File No. 333-238174), filed May 11, 2020). |
|
|
|
99.4 |
|
Axsome Therapeutics, Inc. Form of Restricted Stock Unit Agreement (Executives and Non-Employee Directors) pursuant to the Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 99.4 to the Company’s Registration Statement on Form S-8 (File No. 333-238174), filed May 11, 2020). |
|
|
|
107* |
|
Filing Fee Table. |
* Filed herewith
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on this 5th day of August, 2024.
|
|
|
|
AXSOME THERAPEUTICS, INC. |
|
|
|
|
By |
/s/ Herriot Tabuteau, M.D. |
|
|
Herriot Tabuteau, M.D. |
|
|
Chief Executive Officer |
|
|
|
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
That each person whose signature appears below constitutes and appoints Herriot Tabuteau, M.D., Chief Executive Officer, and Nick Pizzie, Chief Financial Officer, and each of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Herriot Tabuteau, M.D. |
|
Chief Executive Officer and Chairman of the Board (Principal Executive Officer) |
|
August 5, 2024 |
Herriot Tabuteau, M.D. |
|
|
|
|
|
|
|
|
/s/ Nick Pizzie, CPA, M.B.A. |
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
|
August 5, 2024 |
Nick Pizzie, CPA, M.B.A. |
|
|
|
|
|
/s/ Mark Coleman, M.D. |
|
Director |
|
August 5, 2024 |
Mark Coleman, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Roger Jeffs, Ph.D. |
|
Director |
|
August 5, 2024 |
Roger Jeffs, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Susan Mahony, Ph.D., M.B.A. |
|
Director |
|
August 5, 2024 |
Susan Mahony, Ph.D., M.B.A. |
|
|
|
|
|
/s/ Mark Saad |
|
Director |
|
August 5, 2024 |
Mark Saad |
|
|
|
|
Exhibit 5.1
DLA Piper LLP (US)
51 John F. Kennedy Parkway, Suite 120
Short Hills, New Jersey 07078
www.dlapiper.com
T: 973-520-2550
F: 973-520-2551
Attorney Responsible for Short Hills Office:
Emilio Ragosa
August 5, 2024
Axsome Therapeutics, Inc.
One World Trade Center, 22nd Floor
New York, New York 10007
|
|
Re: |
Axsome Therapeutics, Inc. - Registration Statement on Form S-8 |
Dear Ladies and Gentlemen:
We have acted as counsel to Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Act”). The Registration Statement relates to the registration of 1,894,054 shares (the “Plan Shares”) of the Company’s common stock, par value $0.0001 per share, issuable under the Axsome Therapeutics, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan (the “Plan”), as referenced in the Registration Statement.
In connection with this opinion letter, we have examined the Registration Statement and originals, or copies certified or otherwise identified to our satisfaction, of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws of the Company and such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.
We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies.
Based upon the foregoing, we are of the opinion that the Plan Shares have been duly authorized and, when and to the extent issued in accordance with the terms of the Plan and any award agreement entered into under the Plan, the Plan Shares will be validly issued, fully paid and nonassessable.
The opinion expressed herein is limited to the Delaware General Corporation Law.
We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the U.S. Securities and Exchange Commission thereunder.
Very truly yours,
/s/ DLA Piper LLP (US)
DLA Piper LLP (US)
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 23, 2024 relating to the financial statements of Axsome Therapeutics, Inc. and the effectiveness of Axsome Therapeutics, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Axsome Therapeutics, Inc. for the year ended December 31, 2023.
/s/ Deloitte & Touche LLP
Morristown, New Jersey
August 5, 2024
Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan of our report dated February 27, 2023, with respect to the consolidated financial statements of Axsome Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
New York, NY
August 5, 2024
159592990N/A0001579428S-8EX-FILING FEES000157942812024-08-052024-08-0500015794282024-08-052024-08-05xbrli:pureiso4217:USD
Exhibit 107
Calculation Of Filing Fee Tables
Form S-8
(Form Type)
Axsome Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Security Type |
|
Security Class Title |
|
Fee Calculation Rule |
|
Amount Registered(1)(2) |
|
|
Proposed Maximum Offering Price Per Unit(3) |
|
|
Maximum Aggregate Offering Price |
|
|
Fee Rate |
|
|
Amount of Registration Fee |
|
Equity |
|
Common stock, $0.0001 par value per share |
|
Rule 457(c) and Rule 457(h) |
|
|
1,894,054 |
|
|
$ |
84.26 |
|
|
$ |
159,592,990 |
|
|
$ |
0.0001476 |
|
|
$ |
23,556 |
|
Total Offering Amounts |
|
|
$ |
23,556 |
|
Total Fee Offsets |
|
|
|
— |
|
Net Fee Due |
|
|
$ |
23,556 |
|
|
|
|
|
|
|
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's common stock, $0.0001 par value per share (the "Common Stock") that becomes issuable under the Registrant's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. |
|
|
|
|
(2) |
This Registration Statement covers 1,894,054 shares of the Registrant's Common Stock, which are issuable pursuant to the Plan. |
|
|
|
|
(3) |
Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $84.26, the average of the high and low prices of the Registrant's common stock as reported on The Nasdaq Global Market on August 2, 2024. |
v3.24.2.u1
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
ffd_FeeExhibitTp |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:feeExhibitTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
ffd_Securities424iNa |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:naItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
ffd_SubmissionLineItems |
Namespace Prefix: |
ffd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
ffd_SubmissnTp |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
Offerings - Offering: 1
|
Aug. 05, 2024
USD ($)
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common stock, $0.0001 par value per share
|
Amount Registered |
1,894,054
|
Proposed Maximum Offering Price per Unit |
84.26
|
Maximum Aggregate Offering Price |
$ 159,592,990
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 23,556
|
Offering Note |
|
|
|
|
|
|
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's common stock, $0.0001 par value per share (the "Common Stock") that becomes issuable under the Registrant's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. |
|
|
|
|
(2) |
This Registration Statement covers 1,894,054 shares of the Registrant's Common Stock, which are issuable pursuant to the Plan. |
|
|
|
|
(3) |
Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $84.26, the average of the high and low prices of the Registrant's common stock as reported on The Nasdaq Global Market on August 2, 2024. |
|
X |
- DefinitionThe amount of securities being registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_AmtSctiesRegd |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegativeDecimal2ItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal amount of registration fee (amount due after offsets).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_FeeAmt |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegative1TMonetary2ItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_FeeRate |
Namespace Prefix: |
ffd_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCheckbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_FeesOthrRuleFlg |
Namespace Prefix: |
ffd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe maximum aggregate offering price for the offering that is being registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_MaxAggtOfferingPric |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegative100TMonetary2ItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe maximum offering price per share/unit being registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_MaxOfferingPricPerScty |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegativeDecimal4lItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_OfferingNote |
Namespace Prefix: |
ffd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe title of the class of securities being registered (for each class being registered).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_OfferingSctyTitl |
Namespace Prefix: |
ffd_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionType of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_OfferingSctyTp |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:securityTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
ffd_OfferingTable |
Namespace Prefix: |
ffd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
ffd_PrevslyPdFlg |
Namespace Prefix: |
ffd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
ffd_OfferingAxis=1 |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_FeesSummaryLineItems |
Namespace Prefix: |
ffd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_NetFeeAmt |
Namespace Prefix: |
ffd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_TtlFeeAmt |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegative1TMonetary2ItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_TtlOfferingAmt |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegative1TMonetary2ItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230
+ Details
Name: |
ffd_TtlOffsetAmt |
Namespace Prefix: |
ffd_ |
Data Type: |
ffd:nonNegative1TMonetary2ItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Axsome Therapeutics (NASDAQ:AXSM)
過去 株価チャート
から 8 2024 まで 9 2024
Axsome Therapeutics (NASDAQ:AXSM)
過去 株価チャート
から 9 2023 まで 9 2024